Drug Repurposing for Drug Development in Stroke
Drug Repurposing for Drug Development in Stroke
复制标题
DOI：
10.1592/phco.30.pt2.51s
复制
发表时间：
2010-07-01
期刊：
影响因子：
4.1
通讯作者：
Fagan, Susan C.
中科院分区：
文献类型：
--
作者：
Fagan, Susan C.
治疗急性中风的新疗法的发展充满了昂贵和令人失望的失败。重新利用已知安全的药物提供了一种风险较低的替代方案。研究人员正在使用药物再利用，即利用已上市药物的二级活性，寻找具有多种作用机制的药物，包括血管保护。保护缺血性脉管系统可能促进神经元恢复，并对中风患者有长期的益处。目前临床上常用药物或器械再灌注和急性阿司匹林治疗来减少缺血性脑卒中致残。将来可能会使用他汀类药物、血管紧张素受体阻滞剂、米诺环素和促红细胞生成素等生长因子等药物。事实上，血管紧张素II受体阻滞剂坎地沙坦的血管保护作用已经在急性缺血性中风的临床试验中得到证实。
The development of new treatments for acute stroke has been fraught with costly and spectacularly disappointing failures. Repurposing of drugs already known to be safe provides a lower risk alternative. Investigators are using drug repurposing, in which marketed drugs are exploited for their secondary activity, to pursue agents that have multiple mechanisms of action, including vascular protection. Protecting the ischemic vasculature is likely to promote neuronal recovery and have long-lasting benefits for patients with stroke. Currently, reperfusion with drugs or devices and acute aspirin therapy are used clinically to reduce disability due to ischemic stroke. In the future, drugs such as statins, angiotensin II receptor blockers, minocycline, and growth factors such as erythropoietin may be used. In fact, vascular protection with the angiotensin II receptor blocker candesartan has already been demonstrated in a clinical trial of acute ischemic stroke.